Genetically engineered malaria vaccine demonstrates 87% efficacy in phase 1 trial

The Medical News ·
Health & Medicine United Kingdom

The novel, genetically attenuated whole parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.

Read original article on The Medical News →